Polio
Anhang
http://thinktwice.com/Polio.pdf (thinking twice about vaccinations)
[N.Z. Miller]
Medical research journalist and natural health advocate. He is the
author of numerous articles and books on vaccines [Vaccines: Are They Really
Safe and Effective?
(updated and revised 2004); Vaccines, Autism and Childhood Disorders
(2003); Immunizations: The People Speak (1996); and Immunization Theory Versus
Reality (1995)].
He is a frequent guest on radio and TV talk shows, including Donahue and
Montel Williams, where he is often seen and heard debating doctors and other
health officials.
Mr. Miller has a degree in psychology, is the director of the Thinktwice
Global Vaccine Institute (www.thinktwice.com), and is a member of Mensa, the
international
high-IQ society. He lives in Northern New Mexico with his family.
Mr. Miller began his crusade against mandatory vaccines when his son was
born. Very little data could be found on this topic.
His search for the truth led him to scientific journals. There he
discovered numerous studies warning medical practitioners that vaccines are
often unsafe and ineffective.
His shock and anger at the suppression of this information culminated in
his passionate advocacy of health freedom and informed parenting options.
Neil Miller is a health pioneer who presented documentation about
vaccine safety and efficacy problems long before these concerns were made
public. For example, several
ears ago he complained about toxic mercury being put into childhood
vaccines and provided evidence linking vaccines and autismus.
During the past decade, cases of autismus skyrocketed by more than 500%
in countries that use the MMR vaccine. In some parts of the U.S. one of every
150 children is
autistic. Recently, Congress commanded the FDA to remove mercury from
vaccines, and new studies by several world-renowned scientists confirmed an
MMR-autism link.
Despite the many problems uncovered in Mr. Miller’s research, he does
not tell parents to reject the shots: Every year, more than 12,000 people in
the U.S. file
vaccine-damage reports with the FDA documenting serious adverse
reactions to mandated immunizations (children are mainly affected).
The FDA estimates that this represents just 10% of the true rate.
Even these figures pale in comparison to the number of cases of new
diseases scientifically linked to inoculations: MMR and autism, polio vaccines
and cancer, the hepatitis B
vaccine and MS, the Hib vaccine and diabetes, to name just a few. For
these reasons, among others, I am opposed to mandatory vaccines. I do not
recommend for or against
the shots. I want everyone to think through this enigmatic and
controversial subject on their own. I believe that parents are capable of
obtaining the facts and making
knowledgeable choices regarding the care and welfare of their children.
Mr. Miller has publicly debated the pros and cons of mandatory
vaccinations with several pediatricians and other health practitioners [Chief medical
epidemiologist for the
National Immunization Program at the Centers for Disease Control and
Prevention]. He conducts lectures throughout the U.S. and is available to
discuss his research on vaccines.
1. What is polio?
Polio is a contagious disease caused by an intestinal virus that may
attack nerve cells of the brain and spinal cord.
Symptoms include fever, headache, sore throat, and vomiting. Some
victims develop neurological complications, including stiffness of the neck and
back, weak muscles,
pain in the joints, and paralysis of one or more limbs or respiratory
muscles.
In severe cases it may be fatal, due to respiratory paralysis.
2. How is polio contracted?
Polio can be spread through contact with contaminated faeces (by
changing an infected baby’s diapers) or through airborne droplets, in food, or
in water. The virus enters the
body by nose or mouth, then travels to the intestines where it
incubates.
Next, it enters the bloodstream where A anti-polio@ antibodies are
produced.
In most cases, this stops the progression of the virus and the
individual gains permanent immunity against the disease .
Many people mistakenly believe that anyone who contracts polio will
become paralyzed or die. However, in most infections caused by polio there are
few distinctive symptoms.
In fact, 95% of everyone who is exposed to the natural polio virus won’t
exhibit any symptoms, even under epidemic conditions. About 5% of infected
people will experience
mild symptoms, such as a sore throat, stiff neck, headache, and fever -
often diagnosed as a cold or flu. Muscular paralysis has been estimated to
occur in about one of every
1.000 people who contract the disease.
This has lead some scientific researchers to conclude that the small
percentage of people who do develop paralytic polio may be anatomically
susceptible to the disease.
The vast remainder of the population may be naturally immune to the
polio virus.
Injections: Several studies have shown that injections (for antibiotics
or other vaccines) increase susceptibility to polio. In fact, researchers have
known since the early 1900s
that paralytic polio-myelitis often started at the site of an injection.
When diphtheria and pertussis vaccines were introduced in the 1940s,
cases of paralytic poliomyelitis skyrocketed. Documented in Lancet and other
medical journals.
In 1949, the Medical Research Council in Great Britain set up a
committee to investigate the matter and ultimately concluded that individuals
are at increased risk of paralysis
for 30 days following injections; injections alter the distribution of
paralysis; and it did not matter whether the injections were subcutaneous or intramuscular.
Polio cases skyrocketed after diphtheria and pertussis vaccines were
introduced
Diphtheria and Pertussis Vaccines Introduced
Several studies show that injections increase susceptibility to polio.
When diphtheria and pertussis vaccines were introduced in the 1940s, cases of
paralytic polio-myelitis skyrocketed.
This chart shows the average number of polio cases per 100,000 people
during five year periods before and after the vaccines were introduced.
Source: National Morbidity Reports taken from U.S. Public Health
surveillance reports; Lancet (April 18, 1950), pp. 659-63.
A 1992 study, published in the Journal of Infectious Diseases, validated
earlier findings. Children who received DPT (diphtheria, tetanus, and
pertussis) injections were significantly
more likely than controls to suffer paralytic poliomyelitis within the
next 30 days. According to the authors, “this study confirms that injections
are an important cause of
provocative poliomyelitis.”
In 1995, the New England Journal of Medicine published a study showing
that children who received a single injection within one month after receiving
a polio vaccine were 8x
more likely to contract polio than children who received no injections.
The risk jumped 27-fold when children received up to nine injections within one
month after receiving the
polio vaccine. And with ten or more injections, the likelihood of
developing polio was 182x greater than expected.
Why injections increase the risk of polio is unclear. Nevertheless,
these studies and others indicate that “injections must be avoided in countries
with endemic poliomyelitis.”
Health authorities believe that all “unnecessary” injections should be
avoided as well.
Nutritional deficiencies:
A poor diet has also been shown to increase susceptibility to polio. In
1948, during the height of the polio epidemics, Dr. Benjamin Sandler, a nutritional
expert at the
Oteen Veterans’ Hospital, documented a relationship between polio and an
excessive use of sugars and starches. He compiled records showing that
countries with the highest
per capita consumption of sugar [U.S./Britain/Australia/Canada/Sweden
(with over 100 pounds per person per year)] had the greatest incidence of polio.
In contrast, polio was
practically unheard of in China (with its sugar use of only 3 pounds per
person per year).
Dr. Sandler claimed that sugars and starches lower blood sugar levels
causing hypoglycemia, and that phosphoric acid in soft drinks strips the nerves
of proper nourishment.
Such foods dehydrate the cells and leech calcium from the body. A
serious calcium deficiency precedes polio. Weakened nerve trunks are then more
likely to malfunction
and the victim loses the use of one or more limbs.
Researchers have always known that polio strikes with its greatest
intensity during the hot summer months. Dr. Sandler observed that children
consume greater amounts of ice cream,
soft drinks, and artificially sweetened products in hot weather. In
1949, before the polio season began, he warned the residents of North Carolina,
through the newspapers and radio,
to decrease their consumption of these products. That summer, North
Carolinians reduced their intake of sugar by 90%, C and polio decreased by the
same amount!
The North Carolina State Health Department reported 2,498 cases of polio
in 1948, and 229 cases in 1949 (data taken from North Carolina State Health
Department figures).
One manufacturer shipped one million less gallons of ice cream during
the first week alone following the publication of Dr. Sandler’s anti-polio
diet. Soft drink sales were down as well.
But the powerful Rockefeller Milk Trust, which sold frozen products to
North Carolinians, combined forces with soft drink business leaders and
convinced the people that Sandler’s
findings were a myth and the polio figures a fluke. By the summer of
1950 sales were back to previous levels and polio cases returned to “normal”.
3. Can polio be treated?
Paralytic polio is rarely permanent. Usually
there is a full recovery [30-34]. Muscle power begins to return after several
days and continues to improve during the next 12-24 months.
A small percentage of cases will experience residual paralysis. In rare
cases, paralysis of the muscles used to breathe can lead to death.
Treatment mainly consists of putting the patient to bed and allowing the
affected limbs to be completely relaxed. If breathing is affected, a respirator
or ironlung can be used.
Physical therapy may be required.
4. Does a polio vaccine exist?
In 1947, Jonas Salk, an American physician and microbiologist, became
head of the Virus Research Laboratory at the University of Pittsburgh. He was
interested in developing a polio vaccine. In 1952, Salk combined 3 types of
polio virus grown in cultures made from monkey kidneys. Using formaldehyde, he
was able to “kill” or inactivate the viral matter so that it would trigger an
anti-body response without causing the disease. That year he began his initial
experiments on human subjects. In 1953, his findings were published in the
Journal of the American Medical Association.
And in April of 1954 the nation’s first polio immunization campaign,
directed at school children, was launched. However, shortly thereafter hundreds
of people contracted polio from
Salk’s vaccine; many died. Apparently, his “killed-virus” vaccine was
not completely inactivated . The vaccine was redeveloped, and by August 1955
over 4 million doses were administered in the U.S. By 1959, nearly 100 other
countries were using Salk’s vaccine.
In 1957, Albert Sabin, another American physician and micro-biologist,
developed a live-virus (oral) vaccine against polio. He didn’t think Salk’s
killed-virus vaccine would be effective
in preventing epidemics. He wanted his vaccine to simulate a real-life
infection. This meant using an attenuated or weakened for mof the live virus.
He experimented with thousands of monkeys and chimpanzees before isolating a
rare type of polio virus that would reproduce in the intestinal tract without
penetrating the central nervous system. The initial human trials were conducted
in foreign countries.
In 1958, it was tested in the U.S. And in 1963 Sabin’s oral “sugar-cube”
vaccine became available for general use.
5. Which vaccine is in use today?
In 1963, Sabin’s oral vaccine quickly replaced Salk’s injectable shot. It
is cheaper to make, easier to take and appears to provide greater protection,
including “herd immunity” in unvaccinated people. only be given the
killed-virus shot. The oral polio vaccine should only be used in “special
circumstances.
6. Are polio vaccines safe?
When national immunization campaigns were initiated in the 1950s, the
number of reported cases of polio following mass inoculations with the
killed-virus vaccine was significantly greater than before massinoculations,
and may have more than doubled in the U.S. as a whole.
For example,
Vermont reported 15 cases of polio during the one-year report period
ending August 30, 1954 (before mass inoculations), compared to 55 cases of
polio during the one-year period
ending August 30, 1955 (after mass inoculations)
C a 266% increase. Rhode Island reported 22 cases during the before
inoculations period as compared to 122 cases during the after inoculations
period
C a 454% increase. In New Hampshire the figures increased from 38 to
129; in Connecticut they rose from144 to 276; and in Massachusetts they swelled
from 273 to 2027
C a whopping 642% increase (Figure 2) [26:140;29:146;42].
When national immunization campaigns were initiated in the 1950s, the
number of reported cases of polio following mass inoculations with the
killed-virus vaccine was significantly greater than before mass inoculations,
and may have more than doubled in the U.S. as a whole.
Source: U.S. Government statistics.
Doctors and scientists on the staff of the National Institutes of Health
during the 1950s were well aware that the Salk vaccine was causing polio.
Some frankly stated that it was “worthless as a preventive and dangerous
to take.” They refused to vaccinate their own children. Health departments
banned the inoculations.
The Idaho State Health Director angrily declared: “I hold the Salk
vaccine and its manufacturers responsible” for a polio outbreak that killed
several Idahoans and hospitalized
dozens more.
Even Salk himself was quoted as saying: “When you inoculate children
with a polio vaccine you don’t sleep well for two or three weeks.” But the
National Foundation for Infantile Paralysis, and drug companies with large
investments in the vaccine coerced the U.S. Public Health Service into falsely
proclaiming the vaccine was safe and effective.
In 1976, Dr. Jonas Salk, creator of the killed-virus vaccine used in the
1950s, testified that the live-virus vaccine (used almost exclusively in the
U.S. from the early 1960s to 2000)
was the “principal if not sole cause” of all reported polio cases in the
U.S. since 1961. (The virus remains in the throat for one to two weeks and in
the faces for up to two months.
Thus, vaccine recipients are at risk, and can potentially spread the
disease, as long as fecal excretion of the virus continues.
In 1992, the Federal Centers for Disease Control and Prevention (CDC)
published an admission that the live-virus vaccine had become the dominant
cause of polio in the U.S.
In fact, according to CDC figures, every case of polio in the U.S. since
1979 was caused by the oral polio vaccine. Authorities claim the vaccine was
responsible for about eight
cases of polio every year.
However, an independent study that analyzed the government’s own vaccine
database during a recent period of less than five years uncovered 13,641
reports of adverse events
following use of the oral polio vaccine. These reports included 6,364
emergency room visits and 540 deaths. Public outrage at these tragedies became
the impetus for removing the
oral polio vaccine from immunization schedules.
In the mid-1990s, during a period of less than five years, there were
13,641 documented adverse reactions to the oral polio vaccine. 6,364 of these
were serious enough to require
hospital emergency room visits. 540 people died. Source: Vaccine Adverse
Event Reporting System (VAERS); OPV Vaccine Report: Doc. #14.
The following story is typical of the damage associated with oral polio
vaccines: “Four months ago my son was taken to a local clinic for his polio
vaccine. I wasn’t aware that
he was going to have one, and would have prevented it if I had known.
Unfortunately, he changed from that day
C high-pitched screaming, smelly stools, non-stop crying, difficulty in
breathing, high temperature, and lethargy. He also lost weight. Weeks of
sleepless nights for all of us followed.
His development ceased. He had been able to stand and move around, but
he went back to remaining in basically whatever position we left him in.
“My wife was six months pregnant at the time, and about a week after our
son’s polio vaccine, she began to have headaches, loss of balance, muscular
weakness, and frequent tiredness.
I panicked because everything seemed to be pointing to polio infection.
Then, a week after her continuous headaches began, she had to go to the
hospital because there was something wrong with the pregnancy; she lost our
daughter. “I tried to get a polio
test, and to find the cause of this tragic series of events, but the
medical profession was extremely unhelpful.
They laughed at me. I will never know why our son suddenly stopped
growing or why his development regressed. I will never know why we lost our
daughter. The only thing
I am sure about is that the precursor to these events was the
poliovaccine”.
[From an unsolicited e-mail received by the Thinktwice Global Vaccine
Institute—www.thinktwice.com]
Today, fact sheets on polio published by the U.S. Department of Health
and Human Services, warn parents that the inactivated polio vaccine (IPV) can
cause “serious problems or even death...”
The company that manufactures the current inactivated polio vaccine
warns that Guillain-Barré Syndrome, a debilitating ailment characterized by
muscular incapacitation and nervous system damage, “has been temporally related
to administration of an other inactivitated poliovirus vaccine.” And although
this company makes the claim that “no causal relationship
has been established,” it also admits that “deaths have occurred” after
vaccination of infants with IPV. Yet, like the days of old, despite these
“danger alerts,” medical authorities
continue to assure parents that the currently available inactivated
polio vaccine is both safe and effective.
7. How effective are polio vaccines?
Polio is virtually nonexistent in the U.S. today. However, according to
Dr. Robert Mendelsohn, medical investigator and pediatrician, there is no
credible scientific evidence that the vaccine caused polio to disappear. From
1923 to 1953, before the Salk killed-virus vaccine was introduced, the polio
death rate in the U.S. and England had already declined on its
own by 47% and 55%, respectively. Statistics show a similar decline in
other European countries as well. And when the vaccine did become available,
many European countries questioned its effectiveness and refused to systematically
inoculate their citizens. Yet, polio epidemics also ended in these countries.
The polio death rate was decreasing on its own before the vaccine was
introduced
From 1923 to 1953, before the Salk killed-virus vaccine was introduced,
the polio death rate in the U.S. and England had already declined on its own by
47% and 55%, respectively.
Source: International Mortality Statistics (1981) by Michael Alderson.
The standards for defining polio were changed when the polio vaccine was
introduced. The new definition of a polio epidemic required more cases to be
reported.
Paralytic polio was redefined as well, making it more difficult to
confirm, and therefore tally, cases.
Prior to the introduction of the vaccine the patient only had to exhibit
paralytic symptoms for 24 hours. Laboratory confirmation and tests to determine
residual paralysis were not required. The new definition required the patient
to exhibit paralytic symptoms for at least 60 days, and residual paralysis had
to be confirmed twice during the course of the disease.
Also, after the vaccine was introduced cases of aseptic meningitis (an
infectious disease often difficult to distinguish from polio) and coxsackie
virus infections were more often reported as separate diseases from polio. But
such cases were counted as polio before the vaccine was introduced. The
vaccine’s reported effectiveness was therefore skewed.
Polio or aseptic meningitis?
Sample Months
Reported Cases of Polio
Reported Cases of Aseptic Meningitis July 1955 (Before the new polio
definition was introduced.) 273
50
July 1961 (After the new polio definition was introduced.) 65 161
September 1966 (After the new polio definition was introduced)
5256 Cases of polio were more often reported as aseptic meningitis after
the vaccine was introduced, skewing (= Verdrehte) efficacy (= Wirksamkeit) rates.
Source: The Los Angeles County Health Index: Morbidity and Mortality,
Reportable Diseases.
Figure 5. Polio cases were predetermined to decrease when the medical
definition of polio was changed
Source: Congressional Hearings, May 1962; and National Morbidity
Reports taken from U.S. Public Health surveillance reports.
The fact that dubious tactics were used to fabricate efficacy rates was
corroborated by Dr. Bernard Greenberg, chairman of the Committee on Evaluation
and Standards of the American
Public Health Association during the 1950s. His expert testimony was
used as evidence during Congressional hearings in 1962. He credited the
“decline” of polio cases not to the vaccine,
but rather to a change in the way doctors were required to report cases:
“Prior to 1954 any physician who reported paralytic poliomyelitis was doing his
patient a service by way of subsidizing the cost of hospitalization... two
examinations at least 24 hours apart was all that was required... In 1955 the
criteria were changed... residual paralysis was determined 10 to 20 days after
onset of illness and again 50 to 70 days after onset... This change in
definition meant that in 1955 we started reporting a new disease...
Furthermore, diagnostic procedures have continued to be refined. Coxsackie
virus infections and aseptic meningitis have been distinguished from
poliomyelitis... Thus, simply by changes in diagnostic criteria, the number of
paralytic cases was predetermined to decrease... “.
8. Polio vaccines and cancer
In 1959, Bernice Eddy, a brilliant government scientist working in
Biologics at the National Institutes of Health, discovered that polio vaccines
being administered throughout the world
contained an infectious agent capable of causing cancer.
When Eddy attempted to report her findings and halt production of these
contaminated polio vaccines, her government superiors barred her from publicly
revealing the problem.
Instead, her lab and equipment were taken away and she was demoted
[54,55].
In 1960, Drs. Ben Sweet and M.R. Hilleman, pharmaceutical researchers
for the Merck Institute for Therapeutic Research, were credited with
discovering this infectious agent CSV-40,
a monkey virus that infected nearly all rhesus monkeys, whose kidneys
were used to produce polio vaccines. Hilleman and Sweet found SV-40 in all
three types of Albert Sabin’s live oral polio vaccine, and noted the
possibility that it might cause cancer (administered to human babies).
According to Sweet, “It was a frightening discovery because, back then, it was
not possible to detect the virus with the testing procedures we had... We had
no idea of what this virus would do...” Sweet elaborated: “First, we knew that
SV-40 had oncogenic (= cancer-causing) properties in hamsters, which was bad
news. Secondly, we found out that it hybridized with certain DNA viruses...
such that [they] would then have SV-40 genes attached
[to them]...
When we started growing the vaccines, we just couldn’t get rid of the
SV-40 contaminated virus.
We tried to neutralize it, but couldn’t... Now, with the theoretical
links to HIV and cancer, it just blows my mind.”
Further research into SV-40 uncovered even more disturbing information.
This cancer-causing virus was not only ingested via Sabin’s contaminated oral
sugar-cube vaccine, but was directly injected into people’s blood streams as
well. Apparently, SV-40 survived the formaldehyde Salk used to kill microbes
that defiled his injectable vaccine. Experts estimate that between 1954 and
1963, 30 - 100 million Americans and perhaps another 100 million or more people
throughout the world were exposed to SV-40 through ill-conceived polio
eradication campaigns.
Studies published in eminent journals throughout the world appear to
confirm that SV-40 is a catalyst (= Beschleuniger) for many types of cancer.
It has been found in brain tumors and leukemia.
More recently, in 1996, Michele Carbone, a molecular pathologistat
Chicago’s Loyol, a University Medical Center, was able to detect SV-40 in 38%
of patients with bone cancer and
in 58% of those with mesothelioma, a deadly type of lung cancer.
Carbone’s research indicates that SV-40 blocks an important protein that
normally protects cells from becoming malignant.
Polio vaccines and simian virus #40 doi: 10.1588/medver.2004.01.00027
In 1998, a national cancer database was analyzed: 17% more bone cancers,
20% more brain cancers, and 178% more mesotheliomas were found in people who
were exposed to SV-40-tainted polio vaccines. The National Institutes of Health
created a map showing the geographic distribution of contaminated stock. Using
this map, researchers found osteosarcoma bone tumor rates to be 10x higher than
normal in some regions where this tainted vaccine was used.
SV-40-tainted polio vaccines: zones of contamination
Between 1954 and 1963, up to 100 million Americans were inoculated with
SV-40-contaminated polio vaccines.
This chart shows areas of the country in 1955 where 10 million people
received polio vaccines with either no, low, or high amounts of SV-40 in them.
Source: National Institutes of Health.
Perhaps the most alarming aspect of this ongoing simian virus debacle
can be found in other studies suggesting that SV-40, introduced to humans
through the polio vaccine, can be passed from human to human and from mother to
child. A study of nearly 59,000 women found that children of mothers who
received the Salk vaccine between 1959 and 1965 had brain tumors at a rate 13x
greater than children of mothers who did not receive those polio shots.
Another study published in the U.S. medical journal Cancer Research
found SV-40 present in 23% of blood samples and 45% of semen taken from healthy
subjects.
Apparently, the virus is being spread sexually and from mother to child
in the womb. According to biology and genetics professor Mauro Tognon, one of
the study’s authors, this would explain why brain, bone, and lung cancer on the
rise
Ca 30% increase in U.S. brain tumors alone over the past 25 years.
C and why SV-40 was detected in brain tumors of children born after 1965
who presumably did not receive polio vaccines containing the virus [83:163;90].
Despite official denials of any correlation between polio vaccines, SV-40, and
increased cancer rates, by April 2001, 62 papers from 30 laboratories around
the world had reported SV-40 in human tissues and tumors.
The virus was also discovered in pituitary and thyroid tumors, and in
patients with kidney disease. Even the National Cancer Institute issued a
statement that SV-40 “may be associated with human cancer.”
Studies yet to be conducted may provide additional clues about the link
between contaminated polio vaccines, SV-40, and new diseases. But scientists
have their hands full. The latest research has uncovered correlations between
polio vaccines, another monkey virus, and AIDS.
9. Polio vaccines and AIDS
SV-40, the cancer-causing monkey virus found in polio vaccines and
administered to millions of unsuspecting people throughout the world, was just
one of numerous simian viruses known to have contaminated polio vaccines. “As
monkey kidney culture is host to innumerable simian viruses, the number found
varying in relation to the amount of work expended
to find them, the problem presented to the manufacturer is considerable,
if not insuperable,” one early vaccine researcher wrote to a congressional
panel studying the safety of growing
live polio-virus vaccine in monkey kidneys.“
As our technical methods improve we may find fewer and fewer lots of
vaccine which can be called free from simian virus.
According to Harvard Medical School professor Ronald Desrosier, the
practice of growing polio vaccines in monkey kidneys is “a ticking time bomb.”
Evidently, some viruses can live inside monkeys without causing harm. But if
these viruses were to somehow cross species and enter the human population, new
diseases could occur.
Desrosier continued: “The danger in using monkey tissue to produce human
vaccines is that some viruses produced by monkeys may be transferred to humans
in the vaccine, with very
bad health consequences.”
Desrosier also warns that testing can only be done for known viruses,
and that our knowledge is limited to about “2% of existing monkey viruses.”
Craig Engesser, a spokesman for Lederle Laboratories, a large vaccine
manufacturing company, acknowledged that“ you can’t test for something if you
don’t know it’s there.”
Virus detection techniques were crude and unreliable during the 1950s,
60s, and 70s when polio vaccines were initially produced and dispensed.
It wasn’t until the mid 1980s that new and more sophisticated testing
procedures were developed. That was when researchers discovered that about 50%
of all African green monkeys
C the primate of choice for making polio vaccines
C were infected with simian immunodeficiency virus (SIV), a virus
closely related to human immunodeficiency virus (HIV), the infectious agent
thought to precede AIDS. This caused
some researchers to wonder whether HIVs may simply be SIVs “residing in
and adapting to a human host.” It caused others to suspect that SIV may have
mutated into HIV once it was
introduced into the human population by way of contaminated polio
vaccines.
Vaccine authorities were so concerned about the possibility that SIV was
a precursor to HIV, and that polio vaccines were the means of transmission from
monkey to human, that W.H.O.
convened two meetings of experts in 1985 to explore the data and
consider their options. After all, SIV was very similar to HIV and occurred
naturally in the monkey species
predominantly used by vaccine manufacturers [98,100]. Nevertheless, WHO
concluded that the vaccines were safe and insisted that vaccination campaigns
should continue unabated.
Shortly thereafter, Japanese researchers conducted their own
investigation and found that African green monkeys used to produce polio
vaccines had antibodies against SIV.
The implication was clear: monkeys used to produce polio vaccines were
doi: 10.1588/medver.2004.01.00027
natural carriers of a virus that looked and acted like HIV, the
infectious agent linked to AIDS. In 1989, they recommended that monkeys
infected with SIV not be used to make polio vaccines.
In 1990, wild chimpanzees in Africa were found to be infected with a
strain of SIV that was nearly identical to HIV.
Some researchers called it “the missing link” to the origins of human
immunodeficiency virus. And since chimpanzees were used to test viruses for
potential use in vaccines, and were
kept in captivity by research laboratories, they could have been a
source of vaccine contamination. Scientific concerns were also heightened when
researchers found some West Africans who were infected with an SIV-like virus
that was a fundamental twin to HIV. They called it HIV-2, and like the initial
HIV subtype, it was implicated in the development of AIDS. According to Robert
Gallo, expert on the AIDS virus, some versions of the SIV monkey virus are
virtually indistinguishable from some human variants of HIV: “The monkey virus
is
the human virus. There are monkey viruses as close to isolates of HIV-2
as HIV-2 isolates are to each other.
”In May 1991, virus-detection techniques were improved once again, and
researchers found SIV DNA in the kidneys of infected monkeys. Minced monkey
kidneys were (still are) used
to produce the live polio vaccine. SIV was also found in the cancer
cells of an AIDS victim, and in other people as well.
To many researchers, this trail of evidence had become too persuasive to
deny. Apparently, millions of people were infected with monkey viruses capable
of causing AIDS and this cross-species transfer most likely occurred by way of
SIV-contaminated polio vaccines.
10. Didn’t AIDS originate in Africa?
Most historians agree that AIDS originated in Africa. But Salk tested
his vaccine in the U.S., and Sabin’s trials were conducted in Eastern Europe
and the former Soviet Union.
If tainted polio vaccines were responsible for introducing SIV and HIV into
humans, why did the initial cases of AIDS show up on this remote continent? In
March 1951, several years before Drs. Jonas Salk and Albert Sabin would scuffle
over whose vaccine was the true prophylactic, Dr. Hilary Koprowski announced at
a medical conference that he had become the first doctor in history to test a
polio vaccine on humans. His “volunteers” included several institutionalized
children with mental handicaps. They drank the vaccine in chocolate milk.
From 1957 to 1960, after years of
tinkering with monkey kidneys and polio germs, Koprowski tested his own
experimental polio vaccine on 325,000 equatorial Africans, including 75,000
citizens of Leopoldville, Belgian Congo (now Kinshasa, Zaire). Called by
drums, rural natives travelled to local villages where they had a liquid
vaccine squirted into their mouths
98% of the vaccine recipients were infants and toddlers. The youngest
children received 15x the adult dosage. Though Koprowski claimed he had the
backing of the W.H.O.
WHO denied sanctioning the large-scale trials.
In 1959, Dr. Albert Sabin reported in the British Medical Journal that
Koprowski’s polio vaccine used in the African trials contained an
“unidentified” cell-killing virus. It was never identified.
However, in 1986 the earliest known blood sample containing antibodies
against HIV was traced back to 1959.
The serum came from a patient visiting a clinic in Leopoldville. There
is no evidence that HIV infected humans before 1959.
Gerald Myers, a genetic sequencing expert with Los Alamos National
Laboratories in New Mexico, tracked the evolution of HIV and confirmed that
today’s major subtypes of the
AIDS virus in humans appear to have arisen as recently as 1960.
Koprowski’s vaccine was not approved for human use, so it was discontinued in
1960 following the African trials.
Thus, it was only administered to inhabitants of the Belgian Congo,
Rwanda and Burundi.
C the precise area where high levels of HIV infection were identified by
researchers 30 years later.
Furthermore, the AIDS virus is known to infect mucous cells, prevalent
in the mouth. The African vaccines were squirted into people’s mouths. Could
squirting an HIV-contaminated polio vaccine into people’s mouths cause AIDS?
According to Tom Folks, chief retrovirologist at the CDC, “Any time a
person has a lesion in his mouth, then there could be transmission” of the
virus. Dr. Robert Bohannon of Baylor College of Medicine maintains that the
process of squirting the polio vaccine into people’s mouths would tend to
aerosolize some of the liquid. Tiny drops could then go directly into
the lungs, and from there to the blood cells susceptible to infection.
This would have been an efficient mode of HIV transmission.
Disease experts believe that the average time between HIV infection and
the development of AIDS is 8-10 years. If the African polio vaccine was indeed
contaminated with SIV/HIV, initial outbreaks of AIDS would have occurred from
the mid-1960s to early 1970s. This period accurately coincides with the
emergence of AIDS in equatorial Africa.
11. Test the polio vaccines
Authorities are reluctant to acknowledge the possibility that medical
scientists, preoccupied with growing polio vaccines in virus-laden monkey
kidneys, may have been responsible for bringing about the AIDS pandemic. For
example, Dr. David Heymann, who heads the W.H.O.’s Global Program on AIDS,
flatly stated that “the origin of the AIDS virus is of no importance to science
today.”
William Haseltine, a Harvard pathology professor and AIDS researcher
also believes that any discussion about the origin of AIDS is distracting and
nonproductive. “It’s not relevant,” and “I’m not interested in discussing it.” Jonas Salk won’t
discuss the subject either.
He is now working on an AIDS vaccine. Albert Sabin believes “you can’t
hang Koprowski with that.” And Koprowski dismissed the idea with a laugh, then
later claimed “this is a highly
theoretical situation.”
However, samples of the polio vaccines used in Africa are kept in freezers
at the Wistar Institute where Koprowski did much of his research.
They could be tested.
Tom Folks of the CDC thinks it’s a good idea to test the seed stocks of
polio because “any time we can learn more about the natural history [of AIDS],
it helps us understand the pathogenesis and...the transmission.” Robert Gallo
also thinks it’s important to determine whether a monkey virus sparked AIDS.
Questions like this “are of more than academic interest because. answering
them may help avoid future zoonotic catastrophes
C that is, transmission of disease from lower animals to humans.”
Responding to these concerns, some AIDS researchers formally requested
samples of the original polio vaccine seed stocks. But the government will
neither release nor test them because there are “only a small number of vials”
of the material, and tests “might use it all up.”
12. AIDS within the Gay community
If AIDS originated in Africa via contaminated polio vaccines, how did
this disease spread to male homosexuals in America?
In 1974, clinics in New York and
California began experimental treatments for gay men afflicted with herpes.
Therapy consisted of multiple doses of the live polio vaccine. As noted
earlier, this vaccine was produced in the kidneys of the African Green monkey,
a known reservoir for simian immunodeficiency virus (SIV), a likely precursor
to HIV. Beginning in the early 1980s, simultaneous outbreaks of Kaposi sarcoma
and serious opportunistic infections (later associated with AIDS) were reported
among homosexual men (New York City, San Francisco, and Los Angeles).
This timespan coincides with the average incubation period between HIV
infection and the development of AIDS.
In 1982, the CDC concluded that such outbreaks “strongly suggests the
occurrence of a single epidemic of underlying immuno-suppression...” The
following year, HIV was identified as the causative agent. And in 1992, Lancet
published the first scientific explanation showing how repeated doses of
SIV-contaminated polio vaccines may have seeded HIV among American homosexual men.
13. AIDS with no identified risk factor (NIR)
Another unusual event occurred in the 1980s. Hundreds of people
diagnosed with AIDS had no identified risk factor (NIR).
They did not engage in risky behaviors related to AIDS infection.
The CDC also listed numerous children as NIR.
Some parents believe HIV-contaminated polio vaccines infected their
loved ones.
On February 12, 1994, Bruce Williams filed a civil suit against the
American Cyanamid Company, claiming its polio vaccine caused his daughter’s
illness. The suit alleges that
“the live oral poliovirus vaccine was produced, tested, and approved by
the U.S. Food and Drug Administration pursuant to measures inconsistent with
accepted standards of
medical practice.” The lawsuit also asserts that “the product was FDA
approved despite the known presence of contaminants, including retroviruses
such as HIV.”
Walter Kyle, the Williams’ lawyer, identified the specific lots of
vaccine the child received, but the CDC and federal health officials have
refused to test them [134:106]. Kyle believes “The CDC could disprove my entire
hypothesis by testing the vaccines they have in their possession. The fact that
they haven’t done so is evidence there’s something wrong with the vaccine.”
Some researchers believe the true number of NIR cases could be in the
thousands.
When health officials examine people with AIDS, they try to identify a
risk factor. If a patient admits he once had unprotected sex, that becomes his
factor, even though there’s
no proof that is how he was infected. The evidence implicating polio
vaccines grown in monkey kidneys with our current epidemics of cancer and AIDS
continues to grow.
But what if polio vaccines were produced in cow serum? Would that make a
difference?
14. Polio vaccines and Mad Cow disease
Mad cow disease, or bovine
spongiformencephalopathy (BSE) is a progressive neurological disorder of
cattle. Infected cows lose weight, drool, arch their backs, wave their heads,
teeter back and forth, threaten other cows, act crazy, and eventually
die. The first case of the disease was observed in 1984. Since then, BSE has
killed more than 200,000 cows.
Mad cow disease is related to scrapie, a similar disease afflicting
sheep. In fact, authorities believe it spread to cows from sheep when they were
fed scrapie-infected bone meal.
Cruetzfeldt-Jakob disease (CJD) and vCJD (a newly discovered variant)
are the human equivalents of mad cow disease.
They cause a comparable wasting of the brain leading to muscle
incoordination, sensory loss, and mental confusion [139]. It is always fatal.
There is no known cure.
There is very strong evidence that mad cow disease and the newly
discovered variant of Cruetzfeldt-Jakob disease are caused by the same
infectious agent. For example, a 1996 study
showed that monkeys injected with BSE developed symptoms remarkely
similar to vCJD. Another study showed that BSE and vCJD had similar molecular
characteristics
C unlike “classical” CJD [141]. Two later studies, one published in
1997, the other in 1999, appear to confirm that BSE from cattle causes
vCruetzfeldt-Jakob disease in humans.
Researchers think that mad cow disease can be passed from cows to humans
if they ingest BSE-infected beef, or if they receive vaccines contaminated with
BSE.
BSE associated infectious agents
are capable of contaminating polio vaccines because they are not only grown in
monkey kidneys, but in calf serum as well. In fact, many parts of the
cow are used in vaccine production. Glycerol is derived from cow fat;
gelatin and aminoacids come from cow bones; and the growth medium for viruses
and other microorganisms may require cow skeletal muscle, enzymes, and blood.
Authorities knew that vaccines could be infected with BSE associated
transmissible agents as early as 1988. Yet, in England, vaccine manufacturers
waited months before switching
to cows less likely to be infected, and refused to remove current stock
off the shelves and out of doctor’s offices until it was all sold, or expired
five years later towards the end of 1993.
One outraged legislator declared that “the Department of Health was
potentially criminally negligent in not requiring the immediate withdrawal or
cessation of use of vaccines from potentially contaminated sources.”
Despite nation wide apprehension, manufacturers continued to disregard
European guidelines.
Finally, in October 2000, the Department of Health became so concerned
about the likelihood of children being infected with BSE-contaminated vaccines
and falling prey to vCruetzfeldt-Jakob disease (dozens of people, including
children, had already contracted it) that they issued a recall of hundreds of
thousands of polio vaccines made using fetal
bovine serum extracted from British cows
doi: 10.1588/medver.2004.01.00027
In the U.S., authorities waited until December 1993 before issuing a
“recommendation” that U.S. manufacturers not use bovine material from countries
reporting BSE [153]. The FDA issued a second warning to manufacturers in 1996
informing them to“ take whatever steps are necessary to reduce potential risk
of transmission of BSE agent [139,147].” But in March 2000, the FDA discovered
that its “recommendations” were ignored. Vaccines were still being made
in bovine materials obtained from countries reporting BSE [147].
Americans have something else to be concerned about as well. Although
U.S. cows do not exhibit “mad cow symptoms,” every year in the U.S. tens of
thousands of cattle are severely incapacitated;
they cannot stand and walk on their own.
Farm Sanctuary, a national non-profit organization dedicated to halting
irresponsible agricultural practices, believes that these “downed” animals may
harbor a new variant of BSE, and is critical of
the Food and Drug Administration’s BSE surveillance efforts [154].
Despite early warning signs, downed cows are not examined for a new
variant of BSE, and have not been ruled out of vaccine production [154].
Dr. Richard Marsh of the Department of Animal Health and Biomedical
Sciences at the University of Wisconsin, Madison, conducted research providing
evidence that downed cattle in the U.S. may harbor a new variant of mad cow
disease.
He inoculated cows with TME, a variant of BSE. They became “downed”
instead of “mad” [155].
Other scientists inoculated cows with scrapie from U.S. sheep. They,
too, became “downed” instead of “mad” [156].
Responding to the FDA’s apparent indifference, Farm Sanctuary issued the
following statement: “We are distressed that economic priorities have tended to
take precedence over the health of
consumers. We are also concerned that, like in Britain, a powerful
economic incentive exists to ignore evidence that BSE, or a variant of BSE,
exists in the U.S. We urge the FDA to examine the
scientific evidence regarding BSE carefully and to act in the interest
of American consumers [154].”
Regardless, the FDA did not modify its BSE surveillance policies, and
vaccines made in bovine material obtained from countries reporting BSE were not
going to be removed from the market for at least another year, until 2002
C after all existing stock had been purchased and consumed [139,147].
15. More animal viruses
Thousands of viruses and other potentially infectious micro-organisms
thrive in monkeys and cows, the preferred animals for making polio vaccines
[83:159]. SV-40, SIV, and BSE associated
transmissible agents are just three of the disease-causing agents
researchers have isolated.
For example, scientists have known since 1955 that monkeys host the “B”
virus, foamy agent virus, haemadsorption viruses, the LCM virus, arboviruses,
and more [157]. Bovine immunodeficiency
virus (BIV), similar in genetic structure to HIV, was recently found in
some cows [103:100].
In 1956, respiratory syncytial
virus (RSV) was discovered in chimpanzees [158]. According to Dr. Viera
Scheibner, who studied more than 30,000 pages of medical papers dealing with
vaccination,
RSV viruses “formed prominent contaminants in polio vaccines, and were
soon detected in children [159].”
They caused serious cold-like symptoms in small infants and babies who
received the polio vaccine [159]. In 1961, the Journal of the American Medical
Association published two studies confirming
a causal relationship between RSV and “relatively severe lower
respiratory tract illness [160].” The virus was found in 57% of infants with
bronchiolitis or pneumonia, and in 12% of babies with a
milder febrile respiratory disease [161]. Infected babies remained ill
for three to five months [161]. RSV was also found to be contagious, and soon
spread to adults where it has been linked to the
common cold [162].
Today, RSV infects virtually all infants by the age of two years, and is
the most common cause of bronchiolitis and pneumonia among infants and children
under one year of age [163]. It also causes
severe respiratory disease in the elderly [164]. RSV remains highly
contagious and results in thousands of hospitalizations every year; many people
die from it [165].
Ironically, scientists are developing a vaccine to combat RSV [166]
C the infectious agent that very likely entered the human population by
way of a vaccine [159].
Dr. John Martin, a professor of pathology at the University of Southern
California, has been warning authorities since 1978 that other dangerous monkey
viruses could be contaminating polio vaccines.
In particular, Martin sought to investigate simian cytomegalovirus
(SCMV), a “stealth virus” capable of causing neurological disorders in the
human brain. The virus was found in monkeys used for
making polio vaccines. The government rebuffed his efforts to study the
risks [83:159–61]. However, in 1995, Martin published his findings implicating
the African green monkey as the probable source
of SCMV isolated from a patient with chronic fatigue syndrome [167].
In 1996, Dr. Howard B. Urnovitz,
a microbiologist, founder and chief science officer of Calypte Biomedical in
Berkeley,
California spoke at a national AIDS conference where he revealed that up
to 26 monkey viruses may have been in the original Salk vaccines. These
included the simian equivalents of humane chovirus,
coxsackie, herpes (HHV-6, HHV-7, and HHV-8), adenoviruses, Epstein-Barr,
and cytomegalovirus [168-170]. Urnovitz believes that contaminated Salk
vaccines given to U.S. children between 1955
and 1961 may have set this generation up for immune systemdamage and
neurological disorders. He sees correlations between early polio vaccine
campaigns and the sudden emergence of human T-cell leukemia, epidemic Kaposi’s
sarcoma, Burkitt’s lymphoma, herpes, Epstein-Barr and chronic fatigue
syndrome[168:1].
Urnovitz also discussed “jumping
genes”—normal genes that may recombine with viral fragments to form new hybrid
viruses called chimeras. He believes that this is exactly what happened when
monkey viruses and human genes were brought together during early polio
vaccine campaigns. And because the chimera “has the envelope of a normal human
gene,” typical cures won’t work.
How do you develop a vaccine or other antidote against the body’s own
DNA [168:1-4;171]?
16. Mutated polio strains
Several years ago, the W.H.O.
launched the Global Polio Eradication Initiative, with 2000 as its target date
for eliminating the disease. However, by 2000 it became clear that not only was
polio still
around, but new strains of the disease -derived from the vaccine itself-
were emerging [172]. Researchers first noticed something unusual in 1983.
Outbreaks of polio in Egypt were being caused by
a “vaccine-derived” polio virus [173].
In 1993, Dr. Radu Crainic of the Pasteur Institute, discovered that
strains of the polio virus have the ability to spontaneously recombine with
themselves and create new strains.
Crainic showed that if you vaccinate a child with polio strains 1, 2,
and 3, you can produce a new strain, strain 4, out of the child’s stool.
Crainic concluded that the polio vaccine creates favorable conditions
contributing to the evolution of viral “recombinations” [174].
In October 2000, virologist Hiromu Yoshida of Japan’s National Institute
of Infectious Diseases in Tokyo reported finding a new infectious polio virus
in Japanese rivers and sewage. Genetic
sequencing confirmed that the virus had mutated from the polio vaccine
and regained much of its original virulence [175]. According to Yoshida, it
poses a “persistent environmental threat [172].”
In December 2000, researchers reported on a polio outbreak in Haiti and
the Dominican Republic that resulted in numerous cases of flaccid paralysis
[173]. Laboratory examinations confirmed
health authorities’ worst suspicions: the disease was caused by “an
unusual viral derivative” of the polio vaccine. The virus demonstrates genetic
similarity to the parent vaccine strain, “
but it has assumed the neurovirulence and transmissibility” of the wild
polio virus [173]. Health officials are obviously concerned, “because a wild
poliovirus has not circulated in the Western
Hemisphere since 1991,” and if the newly mutated polio virus spreads, it
could cause new epidemics of the disease (Figure 8) [173].
Figure 8. Polio eradication with vaccines: a vicious cycle?
The wild polio virus brought about the development of polio vaccines,
which spawned mutations of the polio virus, resulting in new “vaccine-derived”
wild polio viruses.
Source: Virology 1993; 196:199-208; Lancet (October 28, 2000); Reuters
Medical News (December 4, 2000)
17. How is today’s polio vaccine produced?
Despite the polio vaccine’s long history of causing polio, and the
manufacturer’s inability to protect the public from dangerous microorganisms
that perpetually contaminate their ever growing
repertoire of “new and improved” products, the currently availble
inactivated, or “killed-virus” polio vaccine continues to be manufactured in
much the same way as earlier versions.
Animal matter and questionable drugs are still used. In the U.S.,
today’s polio vaccine is a sterile suspension of three types of poliovirus.
“The viruses are grown in cultures of a continuous line
of monkey kidney cells...supplemented with newborn calf serum...”
The vaccine also contains two antibiotics (neomycin and strepto-mycin),
in addition to formaldehyde as a preservative [3].
In Canada an ada, the inactivated polio vaccine is produced in “human
diploid cells” instead of monkey kidneys [83:163]. Some researchers believe
this is a safer alternative. According to Barbara Loe
Fisher, president of the National Vaccine Information Center in Vienna,
Virginia, “With mounting evidence that cross-species transfer of viruses can
occur, the U.S. should no longer be using animal
tissues to produce vaccines [91].” However, Dr. Arthur Levine of the
National Institutes of Health believes that making polio vaccines using human
cells isn’t risk-free either, “because they must be
tested for human infections [176].”
18. Are positive changes possible?
Government officials worry that
even debating the issue will frighten parents. Levine probably speaks for many
people within the vaccine industry when he declares: “We do a grave disservice
to the public if we were now to question the safety of the current polio
vaccines... [176]”
But Barbara Loe Fisher would like to see changes in the way vaccine
safety is governed. She believes that agencies like the FDA have an inherent
conflict of interest because of their mandate to
promote universal vaccination on the one hand and regulate vaccine
safety on the other. “Who’s minding the store when the FDA has allowed drug
companies to produce vaccines grown on
contaminated monkey kidneys?
” Fisher asks. “What happened to protecting the public health [60]?”
Dr. John Martin agrees. He believes that we need to immediately
determine the prevalence of stealth viruses of simian origin in the U.S., and
whether they may be contributing to chronic immune system
and brain disorders in children and adults [177]. Dr. Urnovitz is even
more resolute in his convictions. He thinks that an extensive study of human
exposure to simian microbes is long overdue.
“Half of the people in this country are baby boomers who were born
between 1941 and 1961 and are at high risk for having been exposed to polio
vaccines contaminated with monkey viruses.
Are we just a time bomb waiting to happen, waiting to develop lupus,
Alzheimer’s and Parkinson’s disease [168:4,5;169]?”
Urnovitz also challenged medical science to prove him wrong. “What we
are saying here is that there is a strong probability that no human
retroviruses existed before the polio vaccines...
You have to realize that if you mess around with nature, you’re going to
pay the price... The objective here is a better, healthier world...
[168:4,5;169;171]”
References
[1]
Okonek BM,
et al.
Develop
m
e
n
t
o
f
p
o
l
i
o
v
accines.
Access Excellence Clas-
sic Collection,
February
16, 2001:1. www.acce
ssexcellence.org/AE/AEC
/CC/polio.htm
l
[
2
]
Volk WA, et al.
B
a
sic Microbiology,
4
th
edition.
Philadelphia, PA: J.B.
L
i
ppincott Co.
,
1980:455.
[
3
]
Ph
ysician
’
s Desk
Ref
e
ren
ce (PDR); 5
5
th
edition.
Montvale,
NJ: Medical
E
c
onom
ics,
2001:778.
[
4
]
Bu
rn
et, M., et al.
Th
e
N
a
tural History of I
n
fectious Disease
New York, NY:
Cam
b
r
i
dge Univer
sity
Pr
ess,
1972:16.
[
5
]
Neustaedter
R.
The Vaccine Guide
. Berkeley, Calif
ornia: North
Atlantic
Books,
1996:107–8
[
6
]
Baby Center. The Polio Vacci
ne (0-12 m
onths).
www.babycenter.
com
/
r
e
fcap/155.
htm
l
?
C
P_bid=
[7]
Moskowitz R.
I
m
m
unizations: T
h
e Other
Side.
Mothering
Spr
i
ng
1984:36.
[
8
]
Houchaus. Ueber Poliom
y
elitis acuta.
Munch Med W
o
chenschr
1909;
56:2353–55.
[
9
]
Lam
b
ert SM. A yaws cam
paign and an
epidem
ic of
poliom
y
elitis in West-
ern Sam
o
a.
J Trop Med Hyg
1936; 39:41–6.
doi: 10.1588/medver.2004.01.00027
N.Z. Miller/Medical Veritas
1 (2004) 239–251
249
[10]
L
i
ndsay
KW
,
et al.
Neurology and Neurosur
gery I
llustrated.
Ed
in
-
burgh/London/New York: Churchill Livi
ngston, 1986:100. Fi
gure
1
5
.
2
.
P
o
-
lio incidence r
a
tes obtained fr
om
National Mor
b
idity
Repor
ts.
[11]
McCloskey
BP.
T
h
e r
e
lation of pr
ophy
lactic
inoculations to the onset of
poliom
y
letis.
Lancet,
Apr
il 18,
1950:659–63.
[
1
2
]
Gef
f
e
n
DH.
Th
e
in
cid
e
n
ce
o
f
par
a
ly
sis occur
r
i
ng in L
ondon childr
e
n within
four
weeks after
im
m
unization.
Med Officer
1950;83:137–40.
[13]
Mar
tin JK.
L
o
cal par
a
ly
si
s in children
af
ter
injections.
Arch Dis Child
1950; 25:1–14.
[
14]
Hill AB, et al. Inoculation
and
po
liom
y
elitis. A statistical investigation in
E
ngland and W
a
les in 1949.
British Medical Journal
1950; ii:1–6.
[15]
Medical Research Council Com
m
itt
ee on Inoculation Proce
d
u
r
e
s
a
n
d
N
e
u
-
ro
l
o
g
i
c
a
l
Le
s
i
o
n
s
. P
o
liom
y
elitis
and prophy
lactic
inoculation.
Lancet
1956;
ii:1223–31.
[
1
6
]
Su
tter R
W
, et al. Attrib
u
t
ab
le ris
k
o
f
DTP (Dip
hther
i
a
and T
e
tanus T
oxoids
a
n
d
P
e
rtussis Vaccine) injection in
provoking paraly
tic poliom
y
elitis during
a large outbreak in Om
an.
Journal of I
n
fectious Disea
s
e
s
1992; 165:444–9.
[
17]
Strebel
PM,
et al. Intram
uscular in
jections within 30 day
s
of im
m
unization
with oral poliovirus vaccine—a risk f
actor f
o
r vaccine-associated paraly
t
i
c
poliom
y
elitis.
New E
ngland J of Med,
Febr
uar
y
23,
1995:500+.
[18]
E
d
itor
i
al.
Pr
ovocation par
a
ly
sis.
Lancet
1992; 340:1005.
[
19]
Wyatt HV. Provocation poliom
y
elitis: neglect
e
d
c
l
i
n
i
c
a
l
obs
e
r
va
t
i
ons
fr
om
1914-
1950.
B
u
lletin of Historical Medicine
1981; 55:543–57.
[
20]
Townsend-Coles,
W.F
and Findlay, G.M. Poliom
y
elitis in relation to i
n
t
r
a
-
m
u
scular
injections of
quinine and other
dr
ugs.
Trans R
Soc Trop
M
e
d
H
y
g
1953; 47:77–81.
[
2
1
]
G
u
ye
r
B
,
e
t
a
l
.
I
n
j
e
c
t
i
o
n
s
a
n
d
p
a
r
a
l
y
t
i
c
p
o
l
i
o
m
y
elitis
in
tropical
Af
rica.
Bull
WH
O
1980; 58:285–91.
[
22]
Bodian
D. Virem
i
a in experim
e
ntal poliom
y
elitis. II. Virem
i
a and the
m
echanism
of
the
>
pr
ovoking
=
ef
f
ect of
injections of
traum
a
.
Amer J Hyg
1954; 60:358–70.
[
23]
Wyatt HV. Incubation of
poliom
y
elitis as calc
u
l
a
t
e
d
fr
om
t
i
m
e
of
e
n
t
r
y
i
n
t
o
th
e cen
tral n
e
r
vous
sy
stem
via
the per
i
pher
a
l ner
v
e pathway
s
.
Rev Infect Dis
1990; 12:547-
56.
[
24]
Wyatt HV, et al. Unnecessary in
jections and paralytic poliom
y
elitis
in
I
ndia.
Trans R
Soc Trop Med Hyg
1992; 86:546–9.
[25]
Chandr
a RK.
Reduced secr
etor
y
antibody
r
e
sponse
to
live
attenuated
m
ea-
sles and poliovirus vaccines
in m
a
lnourished children.
British Medical
Journal
1975; ii:583–5.
[26]
McBean
E
.
The P
o
isoned Needle
. Mokelum
n
e Hill, Calif
ornia: Health
Resear
ch,
1957:116.
[27]
Sandler
B.
A
m
erican Journal of P
a
thology,
Januar
y
1941.
[28]
Sandler
B.
D
i
e
t
P
r
events
Polio
(Milwaukee: Lee Foundation for Nutritional
Resear
ch,
1951)
.
[29]
Allen
H.
Don’
t Get Stuck:
The Case A
gainst V
a
ccinations.
(Old
sm
ar, Flor
-
ida: Natur
a
l Hy
giene Pr
ess,
1985:166.
[
30]
Harry NM. The recovery
period in anterior poliom
y
elitis.
British Medical
Journal
1938; 1:164–7.
[
31]
Sharrard W. Muscle
recovery in poliom
y
elitis.
J B
one Joint Surgery
1955;
37B:63–79.
[32]
Affeldt JE
,
et al.
Functional and
vocational
r
ecover
y
in sever
e
poliom
y
eli-
tis.
Clin Orthop
1958; 12:16–21.
[
3
3
]
H
o
l
l
e
n
b
e
r
g
C
,
e
t
a
l
.
T
h
e
l
a
t
e
e
f
f
e
c
t
s
o
f
s
p
i
n
a
l
p
o
liom
y
elitis.
Can Med A
ssoc
J
1959; 81:343–6.
[34]
Ram
l
ow,
J.
,
et al.
E
p
idem
iology
of the post-
polio sy
ndr
om
e.
A
m
erican
Journal of E
p
idemiology
1992;136:783.
[35]
A Science Ody
ssey
:
People and Discover
i
es.
Salk pr
oduces
polio
vac-
cine.www.pbs.org/wgbh/aso/data
bank/entries/dm
52sa.htm
l
[
36]
Strebel PM., et
al.
Epidem
iology
of
poliom
y
letis in U.S. one decade af
ter
the
last
r
e
por
ted case of indigenous wild vir
u
s associated disease,
Clinical
I
n
fectious Diseases
CDC,
Febr
uar
y
1992:568–79.
[
37]
Gorm
an C. When th
e vaccine causes the polio.
Time
October
30,
1995:83.
[
38]
Shaw D. Unintended casualties in war on polio.
P
h
iladelphia I
nquirer
June
6,
1993:A1.
[39]
Morbidity
and Mortality
Week
ly
Report (MMWR):
CDC. 2000; 49:1–22.
[
40]
Reuters Medical News. CDC pub
lishes Updated Poliom
y
elitis
prevention
recom
m
e
ndations for the
U.S.,
Ma
y
22, 2000. www.id.m
edscape.com
/r
euter
s
/pr
o
f/2000/05/05.
22/20000522plcy
001.
htm
l
[
41]
The Associated Press.
Polio cases caused by vaccine.
The Santa F
e
New
Mexican
,
Januar
y
31,
1997.
[42]
Data taken fr
om
gover
n
m
e
nt statistic
s,
as r
e
por
ted in
an
Associated
Pr
ess
dispatch fr
om
Boston,
August 30,
1955.
[
43]
As reported by Saul Pett in an A
ssociated Press dispatch f
r
om
Pittsburgh,
October
11,
1954.
[44]
W
a
shington P
o
st,
Septem
ber
24,
1976.
[
45]
Am
erican Academ
y of
Pediatrics,
R
e
port of the Committee on I
n
fectious
Diseases:
1986
(Elk Grove Village
, Illinois: AAP):284–5.
[
46]
Institute of
Medicine. An eval
uation of
poliom
y
elitis vaccine policy
op-
tions.
I
O
M P
ublication 88-
04
(
W
ashington
DC: National Academ
y
of Sci-
ences,
1988)
.
[
47]
Vaccine Adverse Event Reporti
ng System
(VAERS), Rockville, MD.
[
48]
IOS. The Polio vaccine coverup
C
OPV Vaccine Report:
Docum
e
nt
#14.
www.ios.com
/
~w1066/poliov6.htm
l
[49]
U.
S.
Depar
t
m
e
nt of Health and
Hum
a
n Services. Polio:
What You Need to
Know,
Atlanta,
GA: CDC,
October
15,
1991:3.
[50]
Mendelsohn
R.
Ho
w to
Ra
ise a
Hea
lth
y Ch
ild
...In
S
p
ite o
f
Y
o
u
r
Do
cto
r
.
(
B
allantine Books,
1984:231.
[51]
Alder
s
on
M.
International Mortality Statistics,
W
a
shington,
DC: Facts on
File,
1981:177–8.
[52]
Hear
ings Befor
e
the Com
m
ittee on I
n
ter
s
tate
and
For
e
ign
Com
m
e
r
ce,
House of Repr
esentatives,
87
th
Congr
ess,
2
nd
Session on HR 10541.
May
1962:94–112.
[53]
Los Angeles County
Health
Inde
x: Morbidity
and Morality
, Reportable
Diseases.
[54]
O’
Her
n
M.
Pr
ofiles: Pioneer
W
o
m
e
n
Scientists. Bethesda, MD: National
Institutes of
Health.
[
55]
Curtis T, Manson P. Scientist’
s Polio Fear Unheeded:
How
U.S.
Re-
searcher’s Warning Was Silenced.
The Houston P
o
st
1992:A1 and A12.
[
56]
Sweet BH, Hillem
a
n MR. The
Vacuol
ating Virus: SV-40. As cited in The
p
o
lio
v
accin
e
an
d
s
i
m
i
an
v
i
ru
s
4
0
b
y
Mo
riarty, T.J
.
www.
chr
onicillnet.
o
r
g
/
online/bensweet.htm
l
[
57]
Moriarty T.J. The polio vaccine
and
sim
i
an virus 40. Online News Index.
www.chronicillnet.org/
online/bensweet.htm
l
[58]
Shah K,
Nathanson N.
Hum
a
n exposur
e
to
SV40.
A
m
erican Journal of
Epidemiology
,
1976;103:1-
12.
[
59]
Curtis T. The origin of
AIDS: A st
a
r
t
l
i
n
g
n
e
w
t
h
e
o
ry attem
p
ts to answer the
question
>
Was it an act of
God or an act of
m
a
n
=
R
o
lling Stone
,
Mar
c
h 19,
1992:57.
[60]
Bookchin D,
Schum
aker
J.
T
a
inted Pol
i
o
V
accine Still Carries Its Threat 40
Years Later.
The B
o
ston Globe,
Januar
y
26,
1997.
[
61]
Innis MD. Oncogenesis and poliom
y
elitis vaccine.
Nature
, 1968;
219:
972–
3.
[
62]
Soriano F, et al. Sim
i
an virus 40 in a
hum
an
cancer.
Nature,
1974;
249:421–4.
[
63]
Weiss
AF,
et al. Sim
i
an virus
40-related antigens in three hum
an m
e
n-
ingiom
as with defined chr
o
m
o
som
e
loss.
Proceedings of the National
A
c
ademy of Science,
1975;72(
2)
:609–13.
[64]
Scher
n
eck S,
et al.
I
s
olation
of a SV-
40-
like papovavir
u
s fr
om
a hum
an
glioblastom
a
.
I
n
ternational Journal of Cancer,
1979;24:523–31.
[
65]
Stoian M, et al. Possible rela
tion between viruses and
orom
axillof
acial
tum
o
r
s
.
I
I
.
Resear
ch on the pr
esence
of SV40 antigen and specific antibod-
ies in patients with orom
axillof
acial tum
o
rs.
V
i
rologie
,
1987;38:35–40.
[
66]
Stoian M, et al. Possible rela
tion between viruses and
orom
axillof
acial
tum
o
r
s
.
I
I
.
Detection of SV40 antigen
and of anti-
SV40 antibodies in pa-
tients with parotid gland tum
o
rs.
V
i
rologie
,
1987;38:41–6.
[67]
Br
avo MP,
et al.
Association be
tween the occur
r
e
nce of
antibodies to sim
-
ian vacuolating vir
u
s 40 and bl
adder
cancer in m
a
le sm
okers.
Neoplasma
,
1988;35:285–8.
[68]
O’
Connell K,
et al.
E
ndothelial cells tr
ansfor
m
e
d by
SV40 T
-
antigen
c
a
u
s
e
Kaposi’
s sar
c
om
a-
like tum
o
r
s
in nude m
i
ce.
A
m
erican Journal of P
a
thol-
ogy
,
1991;139(
4)
:743–9.
[69]
W
e
iner
L
P
,
et al.
I
s
olation of vi
r
u
s r
e
lated to SV40 fr
om
patients
with
pr
o-
gressive m
u
ltifocal
leukoencephalopathy
.
New E
ngland Journal of Medi-
cine
,
1972;286:385–90.
[70]
T
a
buchi
K.
Scr
eening
of hum
an br
ain tum
o
r
s
for
SV-
40-
r
e
lated T
-
antigen.
I
n
ternational Journal of Cancer
1978;21:12–7.
[71]
Meinke
W, et al. Sim
i
an viru
s 40-related DNA sequences in a hum
an brain
tum
o
r.
Neurology
1979;29:1590–4.
[
72]
Krieg
P,
et al. Episom
al sim
i
an
vir
u
s 40 genom
es in hum
an br
ain tum
o
r
s
.
Proceedings of the National Academy of Science
1981; 78:6446-
50.
[73]
Kr
ieg P,
et al.
Cloning of
SV40 genom
es fr
om
hum
an br
ain tum
o
r
s
.
Viro
l-
ogy
1984;138:336–40.
[74]
Geissler
E
.
SV40
in
hum
an intr
acr
anial tum
o
r
s
: passenger
vir
u
s or
onco-
genic
>
hit-and-run
=
agent?
Z Klin Med
,
1986;41:493–5.
doi: 10.1588/medver.2004.01.00027
N.Z. Miller/Medical Veritas
1 (2004) 239–251
250
[75]
Geissler
E
.
SV40 and hum
an br
ain tum
o
r
s
.
P
r
ogress in Medical V
i
rology
,
1990;37:211–22.
[76]
Bergsagel DJ, et al. DNA sequences
sim
ilar to those of sim
i
an virus 40 in
ependy
m
o
m
a
s and chor
oid ple
xus tum
o
r
s
of childhood.
New E
ngland
Journal of Medicine
,
1992;326:988–93.
[77]
Mar
tini,
M.
,
et al.
Hum
a
n br
ain tum
o
r
s
and sim
i
an vir
u
s 40.
Journal of
the
National Cancer Institute,
1995;87(
17)
:1331.
[78]
L
e
dnicky
JA,
et al.
Natur
a
l Sim
i
an Virus 40 Strains are
Present
in
Hum
a
n
Chor
oid Plexus and E
p
endy
m
o
m
a
T
u
m
o
r
s
.
V
i
rology
,
1995;212(
2)
:710–7.
[79]
Tognon M, et al
. Large T Antigen
Coding
Sequence of Two DNA Tum
o
r
Vir
u
ses,
BK and SV-
40,
and
Nonr
andom
Chr
o
m
o
som
e
Changes in T
w
o
Gioblastom
a
Cell Lines.
C
a
n
cer
Gen
e
tics and Cytogenics
,
1996;90(
1)
: 17–
23.
[80]
Vilchez RA,
et al.
Associa
tion between sim
i
an vir
u
s 40 and non-
hodgkin
ly
m
phom
a.
Lancet,
(
M
ar
ch 9,
2002)
,
359: 817–23.
[81]
Car
bone,
M.
,
et al.
SV-
40 L
i
ke Sequences in Hum
a
n Bone T
u
m
o
r
s
.
Onco-
gene
,
1996;13(
3)
:527–35.
[82]
Pass,
HI
,
Car
bone,
M.
,
et al.
E
v
id
ence For
and I
m
plications
of
SV-
40
L
i
ke
Sequences
in Hum
a
n Mesotheliom
a
s.
I
m
portant A
d
vances in Oncology
,
1996:89-
108.
[
83]
Rock,
Andrea. The Lethal Dangers
of
the Billion Dollar Vaccine
Business,
Money
, Decem
ber 1996:161.
[84]
Carlsen,
W.
Rogue virus in the
vaccine: Early
polio vaccine harbored virus
now
f
eared
to cause cancer in hum
ans.
San F
r
ancisco Chronicle,
July
15,
2001:7.
Resear
ch by
Susan Fisher
,
epidem
iologist,
L
o
y
o
la Uni
v
e
r
s
i
t
y
M
e
d
i
-
cal Center.
[
8
5
]
National Institutes of
Health. Zone
s of
Contam
ination:
Globe Staf
f
Graphic.
[86]
Bookchin D, Schum
ach
er J. Tainted polio vaccine still carries
its
threat
40
years later.
The B
o
ston Globe,
Januar
y
26,
1997.
[
87]
SV-40 Contam
ination of
Polio Vaccine.
W
e
ll W
ithin Online,
(Feb
ru
ary 3
,
2001, updated). www.nccn.ne
t/~wwithin/polio.htm
[88]
Rosa FW
,
et al.
Absence of
an
tibody
r
e
sponse to sim
i
an vir
u
s 40 after
inoculation
with
killed-poliovirus
vac
c
i
ne
of m
o
t
h
e
r
s
offs
pr
i
ng w
i
t
h
ne
ur
o-
logical tum
o
r
s
.
New E
ngland Journal
of Medicine,
1988;318:1469.
[89]
Rosa FW
,
et al.
Response to:
Neur
ological tum
o
r
s
in offspr
ing after
inocu-
lation of
m
o
thers with killed poliovirus vaccine.
New E
ngland Journal of
Medicine,
1988,
319:1226.
[90]
Mar
tini
F,
et
al.
SV-
40
E
a
r
l
y
Region and L
a
r
g
e T
Antigen in Hum
a
n Br
ain
T
u
m
o
r
s
,
Per
i
pher
a
l Blood Cells,
and Sp
er
m
Fluids fr
om
Healthy
I
ndividu-
als.
Cancer Research
,
1996;56(
20)
:4820–5.
[91]
Fisher, Barbara. Vaccine safety
c
onsum
er group cites conf
lict of interest in
gover
n
m
e
nt
r
e
por
t
on
cancer
a
n
d
c
o
n
t
a
m
i
n
a
t
e
d
p
o
l
i
o
v
accine link.
National
V
a
ccine I
n
formation Center (
N
V
I
C)
;
Pr
ess Release,
Januar
y
27,
1998.
[92]
National Cancer Institute (June 2001).
[
93]
Koprowksi H. Tin anniversary
of
the developm
ent of
live virus vaccine.
Journal of the A
m
erican Medical A
ssociation
1960;174:972–6.
[
94]
Hayf
lick L, Koprowski H, et al.
Preparation of
poliovirus vaccines in a
hum
an fetal diploid cell str
a
in.
American J Hyg
1962;75:240–58.
[95]
Kopr
owski
H.
I
n
a letter
sent to
the Congr
essional Health and Safety
Sub-
com
m
ittee,
Apr
il 14,
1961.
[
96]
Curtis
T. Expert says test vacci
ne: backs check of
polio stocks f
o
r AIDS
vir
u
s.
The Houston P
o
st,
Mar
c
h 22,
1992:A-
21.
[97]
E
ssex M,
et al.
T
h
e or
igin of
the
AI
DS
vir
u
s.
Scientific American
,
1988;
259:64–71.
[98]
Karpas A. Origin
and Spr
ead of AI
DS.
Nature
,
1990; 348:578.
[
99]
Kyle
WS. Sim
i
an retroviruses,
poliovaccine, and origin of
AIDS.
Lancet
,
1992; 339:600–1.
[100]
Elswood
BF, Stricker RB. Polio
vaccines and the origin of AIDS.
Medical
Hypothesis
,
1994:42:347–54.
[
101]
Myers G, et al.
T
h
e
e
m
e
r
ge
nc
e
of
s
i
m
i
a
n
/
hum
a
n
i
m
m
unode
fi
c
i
e
n
c
y
vi
r
u
s
e
s
.
AIDS
Res Hu
ma
n
Retro
1992:8:373–86.
[102]
W
o
r
k
shop on Sim
i
an Vir
u
s-
40 (
S
V-
40)
: A Possible Hum
a
n Poly
om
avir
us
.
Natio
n
a
l Vaccin
e
In
f
o
rm
atio
n
C
e
n
t
er, J
a
n
u
a
ry 2
7
-
2
8
,
1997.
www.
909shot.
com
/
polio197.
htm
(
I
n
clude
s
a
s
u
m
m
a
r
y
o
f
e
v
i
d
e
n
c
e
p
r
e
s
e
n
t
e
d
a
t
t
h
e
E
i
g
h
t
h
Annual Houston Confer
ence on AI
DS.
)
[103]
Martin
B. Polio vaccines and the or
igin of AIDS: The car
eer of a threaten-
ing idea.
Townsend Letter for Doctors,
Januar
y
1994:97–100.
[104]
Curtis T. Did a polio vaccine
experim
e
nt unleash AIDS in
Africa?
The
W
a
shington Post,
Apr
il 5,
1992:C3+.
[105]
W
o
r
l
d Health Or
ganization.
T
-
ly
m
photr
opic r
e
tr
ovir
u
ses of nonhum
an
prim
ates. WHO inf
o
rm
al m
eeting.
Weekly Epidemiology Records
,
1985;
30:269–70.
[106]
Ohta Y, et
al.
No
evidence for the contam
inati
on of live oral poliom
y
elitis
vaccines with sim
i
an im
m
unodeficiency
virus.
AIDS
,
1989; 3:183–5.
[107]
Huet T, et al. Genetic organizati
on
of
a chim
panzee lentivirus related to
HIV-1.
Nature,
1990; 345:356–9.
[108]
Desr
osier
s
RC.
HI
V-
1
or
igins:
A finger
on the m
i
ssing link.
Nature,
1990;345:288–9.
[109]
Sabin AB.
Pr
oper
ties and behavior
of or
ally
adm
i
nister
ed attenuat
e
d
p
o
l
i
o
-
virus vaccine.
Journal of the A
m
erican Medical
A
ssociation,
1957;
164:1216–23.
[110]
Plotkin SA,
Kopr
owski H,
et al.
Clin
ical tr
ials in infants of
or
ally
adm
i
nis-
tered poliom
y
elitis viruses.
P
e
diatrics
1959;23:1041–62.
[111]
Bar
i
n F,
et al.
Ser
o
logical evidence for
vir
u
s r
e
lated to sim
i
an T
-
ly
m
photr
opic
r
e
tr
ovir
u
s
I
I
I
in r
e
sidents of W
e
st Afr
i
ca.
Lancet
1985;
ii:1387–9.
[112]
Hir
s
ch VM,
Z
ack PM,
Vogel AP
,
Johnson PR.
Sim
i
an im
m
unodeficiency
vir
u
s infection of m
acaques: E
nd-
stag
e disease is characterized by wide-
spread distribution of proviral DNA in tissues.
Journal
of I
n
fectious Dis-
ease,
1991; 163(
5)
:976–88.
[113]
Bohannon RC,
et al.
I
s
olation of
a T
y
pe D r
e
tr
ovir
u
s fr
om
B-
cell
ly
m
pho-
m
a
s of a patient with AI
DS.
Journal of V
i
rology,
1991;65(
11)
:5663–72.
[114]
Khabbaz RF, et al. Sim
i
an im
m
unode
ficiency
virus needlestick
accident
in
a laboratory worker.
Lancet,
1992;340:271–3.
[115]
Gao
F,
et al.
Hum
a
n infection by
genetically
diver
s
e SI
Vsm
-
r
e
lated HI
V-
2
in West Af
rica.
Nature,
1992;358:495–9.
[116]
Giunta S,
et al.
T
h
e pr
im
ate tr
ade and the or
igin of AI
DS vir
u
ses.
Nature,
1987;329:22.
[117]
Seale
J.
Cr
ossing the species bar
r
i
er
C
vir
u
ses and the or
igins of AI
DS in
perspective.
J R
Soc Med,
1989;82:519–23.
[118]
Lecatsas G. Origin of AIDS.
Nature,
1991;351:179.
[119]
Gilks C.
Monkey
s
and m
a
lar
i
a.
Nature,
1991;354:262.
[120]
Gr
m
e
k
MD.
History of A
I
DS:
E
m
ergence and Origin of a Modern P
an-
demic.
Pr
inceton,
NJ: Pr
inceton Univer
sity
Pr
ess,
1990.
[121]
Kopr
owski
H.
Histor
ical
aspec
t
s
o
f
t
h
e
d
e
v
e
l
o
p
m
e
n
t
o
f
l
i
v
e
v
i
r
u
s
v
accine in
poliom
y
elitis.
British Medical Journal,
1960;ii:85–91.
[122]
Lebrun A, et al.
Vaccination
with
the CHAT strain of Ty
pe 1 attenuated
poliom
y
elitis
virus in Leopoldville, Belgian Congo.
Bulletin of the W
o
rld
Health Organization,
1960;22:203–13.
[123]
Klein
A.
Trial by Fury
. New York, NY: Charles Scribner
=
s Sons,
1972.
[124]
Sabin AB. Present position
of im
m
unization against po
l
i
o
m
y
e
litis with live
virus vaccines.
British Medical Journal,
1959;i:663–80.
[125]
Mahm
ias AJ, et al.
Evidence
for
hum
an infection with an HTLV III/LAV-
like vir
u
s in Centr
a
l Afr
i
ca,
1959.
Lancet,
1986;i:1279–80.
[126]
Hum
i
ner
D,
et al.
AI
DS in the pr
e-
AI
DS er
a.
Rev Infect Dis,
1987; 9:1102–
8.
[127]
Corbitt G, et al. HIV
infection in Manchester, 1959.
Lancet,
1990;ii:51.
[128]
Cohen J. Debate on
AIDS
origin: Rolling Stone
weighs in— Controversial
article angers vaccine experts by claim
i
ng AIDS coul
d
ha
ve
be
e
n
s
p
r
e
a
d
by
polio vaccines in Af
rica.
Science
,
Mar
c
h 1992:1505.
[129]
Hr
dy
DB.
Cultur
a
l pr
actices contr
i
buting to
the
tr
ansm
ission
of
hum
an
im
m
unodeficiency
vir
u
s in Afr
i
ca.
Rev Infect Dis,
1987; 9:1109–19.
[130]
Sonnet
J,
et al.
E
a
r
l
y
AI
DS cases or
iginating fr
om
Z
a
ir
e and Bur
t
undi
(
1962-
1976)
.
Scandinavian Journal of
I
n
fectious Disease,
1
9
87;19:511–7.
[131]
Gallo
R.
V
i
rus Hunting.
New York: HarperCollins, 1991.
[132]
T
a
ger
A.
Pr
elim
inar
y
r
e
por
t on the tr
eatm
e
nt of r
ecur
r
ent her
p
es sim
p
lex
with poliom
y
elitis
vaccine(Sabin’s).
Dermatologica,
1974;149:253–5.
[133]
Center
s for
Disease Contr
o
l T
a
sk For
ce on Kar
posi’
s Sar
c
om
a
a
n
d
Oppor
tunistic I
n
fections.
E
p
idem
iological aspects of the cur
r
e
nt outb
r
e
a
k
o
f
Kaposi’
s
sar
c
om
a and oppor
tunistic infections.
New E
ngland Journal of
Medicine,
1
9
8
2
;
3
0
6
:
2
5
2
.
[134]
Kor
n
P.
T
h
e New AI
DS My
ster
y
.
R
e
dbook,
July
1994:82.
[135]
Painter
K.
Usual r
outes of infection
r
u
led
out:
12-
y
ear
-
o
ld’
s
par
e
nts
blam
e
polio vaccine, but scientis
ts discount that theory
.
USA
Today,
Mar
c
h 8,
1994:A1.
[136]
E
x
tr
acted fr
om
a copy
of the civil
tor
t
claim
(
U
.
S
.
Distr
i
ct
Cour
t,
New
Jersey
).
[137]
Seven per
cent of the
AI
DS
patient
s in Michigan have no identifiable cause
of
AIDS. As reported to the
Thinktwice Global Vaccine Institute.
[138]
Cowley
G.
Cannibals to cows
: T
h
e path of a deadly
disease.
Newsweek,
Mar
c
h 12,
2001:53.
[139]
Center
for
Biologics E
v
aluati
on and Resear
ch.
Bovine Spongifor
m
E
n
-
cephalopathy
(
B
SE
)
.
FDA,
January
23, 2001.
[www.fda.gov/cber
/bse/bseqa.htm
]
doi: 10.1588/medver.2004.01.00027
N.Z. Miller/Medical Veritas
1 (2004) 239–251
2